Evaluation of the effect of surgical treatment on quality of life with the Dermatology Life Quality Index in patients with facial nonmelanoma skin cancer

dc.contributor.authorÇetinarslan T.
dc.contributor.authorEvrenos M.K.
dc.contributor.authorBilaç C.
dc.contributor.authorÖzyurt B.
dc.contributor.authorTürel Ermertcan A.
dc.date.accessioned2024-07-22T08:07:03Z
dc.date.available2024-07-22T08:07:03Z
dc.date.issued2020
dc.description.abstractSkin cancers are the most common type of cancer. Nonmelanoma skin cancers (NMSCs) are more common than melanoma. Although the mortality rate is low, cancer word can be frightening for patients. Surgery is the main treatment. As skin cancers are most commonly located on the face, undesirable cosmetic results can occur as a result of treatments or due to primary disease. Therefore, the quality of life of patients could be affected. To determine the effect of surgical treatment on quality of life of the patients with facial NMSC using the Dermatology Life Quality Index (DLQI) at baseline and 3 months after surgery. We aimed to see if there was any improvement in quality of life scores after surgery, and to identify factors affecting quality of life. A total of 255 patients; 174 basal cell carcinoma (BCC) (68.2%) and 81 squamous cell carcinoma (SCC) (31.8%) were included in our study. All participants completed DLQI at baseline and 3 months after surgery. The mean total DLQI scores were 6.37 ± 6.28 in patients with BCC, and 6.35 ± 6.16 in patients with SCC. The mean total DLQI scores were 3.96 ± 5.14 in patients with BCC (P <.001), and 4.49 ± 5.24 in patients with SCC (P <.001) 3 months after surgery. In patients with primary skin cancer, all subscale scores and total DLQI scores were worse than the recurrent skin cancer group in both BCC and SCC at baseline. According to the treatment modalities, total DLQI scores and all subscales were worse in the graft group in BCC and SCC patients at baseline. Interestingly, the sex and the type of skin cancer did not affect quality of life, but tumor localization ([auricula OR: 6.45 [95% CI: 1.28-37.47] and eyelid OR:0.20 [95% CI: 0.04-0.96]) treatment procedure ([flap procedure OR: 7.90 [95% CI: 2.64-23.62] and graft procedure OR: 5.47 [95% CI: 1.60-18.71]) and, primary tumor OR:3.86 (95% CI: 1.01-14.78) were significant. The quality of life of skin cancer patients was affected by tumor localization, treatment procedure, primary, or recurrent tumor. The quality of life showed a significant improvement in patients with facial NMSC after surgical treatment. However, the type of NMSC seems to have no effect on the quality of life. © 2020 Wiley Periodicals LLC.
dc.identifier.DOI-ID10.1111/dth.14094
dc.identifier.issn13960296
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13793
dc.language.isoEnglish
dc.publisherBlackwell Publishing Inc.
dc.rightsAll Open Access; Gold Open Access
dc.subjectCarcinoma, Basal Cell
dc.subjectDermatology
dc.subjectHumans
dc.subjectNeoplasm Recurrence, Local
dc.subjectQuality of Life
dc.subjectSkin Neoplasms
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectauricle
dc.subjectbasal cell carcinoma
dc.subjectcancer surgery
dc.subjectcheek
dc.subjectcontrolled study
dc.subjectDermatology Life Quality Index
dc.subjecteyelid cancer
dc.subjectface cancer
dc.subjectfemale
dc.subjectforehead
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectlip cancer
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnon melanoma skin cancer
dc.subjectnose cancer
dc.subjectprimary tumor
dc.subjectprospective study
dc.subjectquality of life
dc.subjectskin flap
dc.subjectskin graft
dc.subjectsquamous cell carcinoma
dc.subjectsuture technique
dc.subjecttumor localization
dc.subjectbasal cell carcinoma
dc.subjectdermatology
dc.subjectquality of life
dc.subjectskin tumor
dc.subjecttumor recurrence
dc.titleEvaluation of the effect of surgical treatment on quality of life with the Dermatology Life Quality Index in patients with facial nonmelanoma skin cancer
dc.typeArticle

Files